Mast Therapeutics (MSTX) Updates on Evaluation of Strategic Options; Received Interest from Private Companies
- Wall St ticks up on megacaps, earnings boost
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Wall St turns higher, gold climbs, oil dips amid economic, geopolitical crosswinds
- US dollar modestly firmer after strong data, Fed comments
- Oil steadies as new sanctions interrupt easing tensions
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
Mast Therapeutics Provides Update On Strategic Direction
November 21, 2016 8:00 AM ESTSAN DIEGO, Nov. 21, 2016 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today provided an update regarding its recently announced campaign to evaluate strategic opportunities. Â
Preliminary Indications of Interest in Reverse Merger Transactions. The Company has received several written indications of interest from privately-held companies, including companies with synergistic clinical-stage drug candidates, and is actively evaluating these opportunities. Other Strategic Opportunities. Concurrently, the Company will continue to explore ways to strategically monetize its... More